TET2 and lymphoma: In myeloid leukemias, e.g., in ∼30% of cases of secondary AML, ∼17% of de novo AML, ∼30% of myelodysplastic syndromes (MDS), ∼50% of chronic myelomonocytic leukemias (CMMLs), and ∼20% of myeloproliferative neoplasms (MNP) show a mutated TET2. Additionally, TET2 is also found to be mutated in certain lymphoid leukemias, e.g., ∼17% of T-cell acute lymphoblastic leukemia (T-ALL), and in certain lymphomas, e.g., ∼33% of angioimmunoblastic T lymphomas, and in ∼12% of diffuse large B-cell lymphomas (73–75).